

## Appendix, Supplemental Digital Content 1: Strategy for Search and Review

### *Inclusion and exclusion criteria*

Each article abstract was reviewed by at least two authors (PP, SV) to determine its relevance to the following factors: addressed at least one focus NCD or its risk factor, included PLHIV in the study, and took place in an LIMC. Articles were designated as 1) included if they addressed all three factors and presented the prevalence rate of the NCD among PLHIV, 2) applicable if they did not include prevalence data but discussed all relevant factors, or 3) excluded if they did not address one or more factors. This resulted in 377 included and 137 applicable articles, which were shared with all of authors to aid in writing the paper. Included articles were further reviewed to identify prevalence rates among PLHIV according to previously identified indicators for each NCD (Supplemental Table). 232 articles were further excluded, because they did not either present a prevalence specific to PLHIV or use one of the agreed upon NCD measurements. All other articles, 152 in total across all NCDs, were included and data was extracted from 141 to populate the Supplemental Table.

### *Variables of interest*

#### HYPERTENSION

Systolic blood pressure (SBP)  $\geq 140$  and/or diastolic blood pressure (DBP)  $\geq 90$  or on hypertension treatment

#### DYSLIPIDEMIA (US National Cholesterol Education Program, Adult Treatment Panel III)

##### ATP III Classification of LDL, Total, and HDL Cholesterol (mg/dL)

###### LDL Cholesterol – Primary Target of Therapy

<100	Optimal
100-129	Near optimal/above optimal
130-159	Borderline high
160-189	High
$\geq 190$	Very high

###### Total Cholesterol

<200	Desirable
200-239	Borderline high
$\geq 240$	High

###### HDL Cholesterol

<40	Low
$\geq 60$	High

Based on ATP III, we defined dyslipidemia using the following conservative cut-offs:

Total Cholesterol: TC  $\geq 200$  mg/dl or 5.2 mmol/l

Elevated LDL: LDL-c  $\geq 130$  mg/dl or 3.4 mmol/l

Hypertriglyceridemia: TG  $\geq 150$  mg/dl or 1.7 mmol/l,

Low HDL: HDL-c  $< 40$  mg/dl or 1 mmol/l

#### DIABETES

Fasting blood sugar  $\geq 126$  mg/dl or 7.0 mmol/l

Two hour plasma glucose  $\geq 200$  mg/dl or 11 mmol/l

Oral glucose tolerance test with glucose  $\geq 200$  mg/dl

Hemoglobin A1C  $> 6\%$

#### CERVICAL CANCER

Invasive cervical cancer: stages I-IV

Cervical intraepithelial neoplasia: CIN I-III

Abnormal cytology: low-grade or high-grade squamous intraepithelial lesion

## DEPRESSION

Depression as diagnosed using validated tools for depression screening in PLHIV in LMICs. These include the Kessler mental distress scales (6 & 10), the Hopkins Symptom Checklist (HSCL), the Patient Health Questionnaire-9 (PHQ-9), the Center for Epidemiological Studies Depression Scale (CES-D), and the Edinburgh Post-Natal Depression Scale (EPDS).

### *Search strategy*

The bibliographic databases, PubMed/MEDLINE, Cochrane Library, and Scopus, were searched in February, April, and November 2015, March 2016, and January 2017 to identify peer-reviewed literature on PLWH and NCDs in SSA LMICs. Articles published from January 1, 2010 to December 31, 2016 were included. Search terms used included controlled vocabulary terms (i.e., Medical Subject Headings) and keywords recommended by subject matter experts and by reviewing key articles. Keywords included variations of each key concept: “people living with HIV”, NCDs (i.e., diabetes, cervical cancer, depression, and cardiovascular disease), LMICs in Sub-Saharan Africa, and awareness, behavior change, communication, or dissemination. In addition to literature searches, the bibliographies of key articles and systematic reviews were reviewed for additional relevant literature. EndNote X8 was used to collect, de- duplicate, and review citations.

PubMed/MEDLINE search strategies for each of the four NCDs are included below.

### **Cardiovascular**

(PLWH\* OR PLWHA\* OR "people living with HIV" OR "people living with HIV/AIDS" OR "people living with" OR "people living with aids" OR "people living with hiv" OR "people living with hiv/aids" OR "people living with hiv/aids plwha" OR "people living with hiv/aids plwhas" OR "people living with hiv aids" OR "people living with hiv aids plwha" OR "people living with hiv aids plwhas" OR "people living with hiv and aids" OR "people living with hiv infection" OR "people living with hivs" OR "people living with human immunodeficiency virus" OR "people living with human immunodeficiency virus/acquired immunodeficiency syndrome" OR "people living with human immunodeficiency virus acquired immunodeficiency syndrome" OR "people living with hiv" OR "HIV Infections"[mesh] OR "HIV infection" OR "HIV infections" OR PLWHIV OR "HIV positive" OR "HIV-positive" OR "HIV+" OR "HIV infected" OR "HIV-infected" OR "HIV seropositivity"[mesh] OR "HIV seropositivity") AND (LMIC OR LMICs OR "low- and middle- income countries" OR "low- and middle- income country" OR "low and middle income" OR "low- and middle- income" OR "lower middle income" OR "lmics" OR "lower middle income" OR "lower middle income countries" OR "lower middle income country" OR "lower middle income economies" OR "lower middle income setting" OR "lower middle income settings" OR Cote d'Ivoire[mesh] OR Ethiopia[mesh] OR Kenya[mesh] OR Malawi[mesh] OR South Africa[mesh] OR Uganda[mesh] OR Zambia[mesh] OR Ivory Coast[tiab] OR Cote d'Ivoire[tiab] OR Ethiopia[tiab] OR Kenya[tiab] OR Malawi[tiab] OR South Africa[tiab] OR Uganda[tiab] OR Zambia[tiab] OR "sub Saharan Africa" OR "sub-saharan Africa" OR Africa[tiab] OR Africa[mesh] OR "sub saharan Africa" OR "developing country" OR "developing countries" OR Cameroon[tiab] OR Central African Republic[tiab] OR Chad[tiab] OR Congo[tiab] OR Equatorial Guinea[tiab] OR Gabon[tiab] OR Democratic Republic of the Congo[tiab] OR Burundi[tiab] OR Djibouti[tiab] OR Ethiopia[tiab] OR Kenya[tiab] OR Rwanda[tiab] OR Somalia[tiab] OR Sudan[tiab] OR Tanzania[tiab] OR Uganda[tiab] OR Angola[tiab] OR Botswana[tiab] OR Lesotho[tiab] OR Malawi[tiab] OR Mozambique[tiab] OR Namibia[tiab] OR South Africa[tiab] OR Swaziland[tiab] OR Zambia[tiab] OR Zimbabwe[tiab] OR Benin[tiab] OR Burkina Faso[tiab] OR Cote D'ivoire OR Gambia OR Ghana OR Guinea OR Guinea-Bissau OR Liberia OR Mali OR Mauritania

OR Niger[tiab] OR Nigeria[tiab] OR Senegal[tiab] OR Sierra Leone[tiab] OR Togo[tiab] OR Cameroon[mesh] OR Central African Republic[mesh] OR Chad[mesh] OR Congo[mesh] OR Equatorial Guinea[mesh] OR Gabon[mesh] OR Democratic Republic of the Congo[mesh] OR Burundi[mesh] OR Djibouti[mesh] OR Ethiopia[mesh] OR Kenya[mesh] OR Rwanda[mesh] OR Somalia[mesh] OR Sudan[mesh] OR Tanzania[mesh] OR Uganda[mesh] OR Angola[mesh] OR Botswana[mesh] OR Lesotho[mesh] OR Malawi[mesh] OR Mozambique[mesh] OR Namibia[mesh] OR South Africa[mesh] OR Swaziland[mesh] OR Zambia[mesh] OR Zimbabwe[mesh] OR Benin[mesh] OR Burkina Faso[mesh] OR Cote D'ivoire[mesh] OR Gambia[mesh] OR Ghana[mesh] OR Guinea[mesh] OR Guinea-Bissau[mesh] OR Liberia[mesh] OR Mali[mesh] OR Mauritania[mesh] OR Niger[mesh] OR Nigeria[mesh] OR Senegal[mesh] OR Sierra Leone[mesh] OR Togo[mesh] OR "Africa, Central"[Mesh] OR "Africa, Eastern"[Mesh] OR "Africa, Southern"[Mesh] OR "Africa, Western"[Mesh]) AND (Cardiovascular Diseases[mesh] OR Heart Diseases[mesh] OR hypertension[mesh] OR stroke[mesh] OR cardiovascular OR "heart disease" OR hypertension OR "high blood pressure" OR stroke OR "heart attack" OR "Coronary Disease"[Mesh] OR "Cerebrovascular Disorders"[Mesh] OR "Pulmonary Embolism"[Mesh] OR "Peripheral Arterial Disease"[Mesh] OR "Peripheral Vascular Diseases"[Mesh] OR "Rheumatic Heart Disease"[Mesh] OR "Venous Thrombosis"[Mesh] OR "coronary disease" OR "pulmonary embolism" OR "cerebrovascular disorder" OR "cerebrovascular disease" OR "peripheral arterial disease" OR "rheumatic heart disease" OR "deep vein thrombosis" OR "ischemic heart disease" OR "heart failure" OR "coronary heart disease" OR "cardiovascular disease" OR "Inflammation"[Mesh] OR inflammation OR inflame\* OR "Atherosclerosis"[Mesh] OR atherosclerosis OR "Metabolic Syndrome X"[Mesh] OR "metabolic cardiovascular syndrome" OR "metabolic syndrome" OR "metabolic syndrome X" OR "insulin resistance syndrome X" OR "metabolic X syndrome" OR "cardiovascular biomarker" OR "inflammation biomarker" OR "endothelial function" OR "Interleukin-6"[Mesh] OR IL-6 OR "C-Reactive Protein"[Mesh] OR "C Reactive Protein" OR "C-Reactive Protein" OR "Carotid Intima-Media Thickness"[Mesh] OR "carotid intima media thickness" OR "carotid intima-media thickness" OR "Cholesterol"[Mesh] OR cholesterol OR "Angiography"[Mesh] OR angiography OR "Hydroxymethylglutaryl-CoA Reductase Inhibitors"[Mesh] OR "Hydroxymethylglutaryl CoA Reductase Inhibitors" OR "HMG-CoA Statins" OR "HMG-CoA Reductase Inhibitors" OR "Fluorodeoxyglucose F18"[Mesh] OR 18F-FDG OR "18F FDG" OR "Fluorodeoxyglucose F 18" OR "2-Fluoro-2-deoxy-D-glucose" OR "Venous Thromboembolism"[Mesh] OR "venous thromboembolism" OR cardiometabolic OR "Myocardial Infarction"[Mesh] OR "myocardial infarction" OR "myocardial infarct" OR "Vascular Diseases"[Mesh] OR "vascular disease" OR "Coronary Artery Disease"[Mesh] OR "coronary artery disease" OR "Myocarditis"[Mesh] OR myocarditis OR "Cardiomyopathies"[Mesh] OR cardiomyopathy OR cardiomyopathies OR "cardiac disease" OR "cardiac arrhythmias" OR "Arrhythmias, Cardiac"[Mesh] OR arrhythmia\* OR "myocardial disease" OR "myocardial diseases" OR myocardiopathy OR myocardiopathies OR carditis OR "dyslipidemias"[MeSH] OR dyslipidemia OR hyperlipidemia OR hypercholesterolemia OR hypertriglyceridemia OR triglyceride OR triglycerides OR HDL OR LDL OR VLDL OR "Lipoproteins, HDL"[Mesh] OR "Lipoproteins, LDL"[Mesh] OR "Lipoproteins, VLDL"[Mesh] OR hyperlipoproteinemia OR lipoprotein(a) OR hyperlipidaemia OR hypercholesterolaemia OR hypertriglyceridaemia OR "Blood Pressure"[MeSH] OR "blood pressure" OR "systolic blood pressure" OR "diastolic blood pressure" OR SBP[tiab] OR DBP[tiab])

### **Mental Health**

(PLWH\* OR PLWHA\* OR "people living with HIV" OR "people living with HIV/AIDS" OR "people living with" OR "people living with aids" OR "people living with hiv" OR "people living with hiv/aids" OR "people living with hiv/aids plwha" OR "people living with hiv/aids plwhas" OR "people living with hiv aids" OR "people living with hiv aids plwha" OR "people living with hiv aids plwhas" OR "people living with hiv and aids" OR "people living with hiv infection" OR "people living with hivs" OR "people living with human immunodeficiency virus" OR "people living with human immunodeficiency virus/acquired immunodeficiency syndrome" OR "people living with human immunodeficiency virus acquired immunodeficiency syndrome" OR "people livnig with hiv" OR "HIV Infections"[mesh] OR "HIV infection" OR "HIV infections" OR PLWHIV OR "HIV positive" OR "HIV-positive" OR "HIV+" OR "HIV infected" OR "HIV-infected" OR "HIV

seropositivity"[mesh] OR "HIV seropositivity") AND (LMIC OR LMICs OR "low- and middle- income countries" OR "low- and middle- income country" OR "low and middle income" OR "low- and middle- income" OR "lower middle income" OR "lmics" OR "lower middle income" OR "lower middle income countries" OR "lower middle income country" OR "lower middle income economies" OR "lower middle income setting" OR "lower middle income settings" OR Cote d'Ivoire[mesh] OR Ethiopia[mesh] OR Kenya[mesh] OR Malawi[mesh] OR South Africa[mesh] OR Uganda[mesh] OR Zambia[mesh] OR Ivory Coast[tiab] OR Cote d'Ivoire[tiab] OR Ethiopia[tiab] OR Kenya[tiab] OR Malawi[tiab] OR South Africa[tiab] OR Uganda[tiab] OR Zambia[tiab] OR "sub Saharan Africa" OR "sub-saharan Africa" OR Africa[tiab] OR Africa[mesh] OR "sub saharan Africa" OR "developing country" OR "developing countries" OR Cameroon[tiab] OR Central African Republic[tiab] OR Chad[tiab] OR Congo[tiab] OR Equatorial Guinea[tiab] OR Gabon[tiab] OR Democratic Republic of the Congo[tiab] OR Burundi[tiab] OR Djibouti[tiab] OR Ethiopia[tiab] OR Kenya[tiab] OR Rwanda[tiab] OR Somalia[tiab] OR Sudan[tiab] OR Tanzania[tiab] OR Uganda[tiab] OR Angola[tiab] OR Botswana[tiab] OR Lesotho[tiab] OR Malawi[tiab] OR Mozambique[tiab] OR Namibia[tiab] OR South Africa[tiab] OR Swaziland[tiab] OR Zambia[tiab] OR Zimbabwe[tiab] OR Benin[tiab] OR Burkina Faso[tiab] OR Cote D'ivoire OR Gambia OR Ghana OR Guinea OR Guinea-Bissau OR Liberia OR Mali OR Mauritania OR Niger[tiab] OR Nigeria[tiab] OR Senegal[tiab] OR Sierra Leone[tiab] OR Togo[tiab] OR Cameroon[mesh] OR Central African Republic[mesh] OR Chad[mesh] OR Congo[mesh] OR Equatorial Guinea[mesh] OR Gabon[mesh] OR Democratic Republic of the Congo[mesh] OR Burundi[mesh] OR Djibouti[mesh] OR Ethiopia[mesh] OR Kenya[mesh] OR Rwanda[mesh] OR Somalia[mesh] OR Sudan[mesh] OR Tanzania[mesh] OR Uganda[mesh] OR Angola[mesh] OR Botswana[mesh] OR Lesotho[mesh] OR Malawi[mesh] OR Mozambique[mesh] OR Namibia[mesh] OR South Africa[mesh] OR Swaziland[mesh] OR Zambia[mesh] OR Zimbabwe[mesh] OR Benin[mesh] OR Burkina Faso[mesh] OR Cote D'ivoire[mesh] OR Gambia[mesh] OR Ghana[mesh] OR Guinea[mesh] OR Guinea-Bissau[mesh] OR Liberia[mesh] OR Mali[mesh] OR Mauritania[mesh] OR Niger[mesh] OR Nigeria[mesh] OR Senegal[mesh] OR Sierra Leone[mesh] OR Togo[mesh] OR "Africa, Central"[Mesh] OR "Africa, Eastern"[Mesh] OR "Africa, Southern"[Mesh] OR "Africa, Western"[Mesh]) AND (mental health[mesh] OR "mental health" OR "mental illness" OR mental disorders[mesh] OR "mental disorders" OR "mental disorder" OR depression OR depression[mesh] OR "depressive disorder"[mesh] OR depressed OR "psychiatric illness" OR "psychiatric disorder" OR "mood disorder" OR "mood disorders" OR "psychosocial stress" OR Schizophrenia OR "psychiatric illness" OR "neuropsychiatric disorder" OR "neuropsychiatric disorders" OR "common mental disorders" OR psychosis OR "psychotic disorder" OR "HIV dementia" OR "HIV encephalopathy" OR "mental hospital" OR "psychiatric hospital" OR "Trauma and Stressor Related Disorders"[Mesh] OR "Mood Disorders"[Mesh] OR "Anxiety"[Mesh] OR "Suicide"[Mesh] OR "Suicidal Ideation"[Mesh] OR "Schizophrenia Spectrum and Other Psychotic Disorders"[Mesh] OR "Schizophrenia"[Mesh] OR "Anxiety Disorders"[Mesh] OR "Adjustment Disorders"[Mesh] OR "Psychotic Disorders"[Mesh] OR "AIDS Dementia Complex"[Mesh] OR "Mental Health Services"[Mesh] OR "Community Mental Health Services"[Mesh] OR "Hospitals, Psychiatric"[Mesh] OR "Substance-Related Disorders"[Mesh] OR "substance abuse" OR "drug abuse" OR "drug dependence" OR "substance addiction" OR MINI OR CIDI OR PHQ-9 OR "Mini International Neuropsychiatric Interview" OR "Composite International Diagnostic Interview" OR "Beck Depression Inventory" OR "bdi depression scores" OR "bdi depression" OR "Patient Health Questionnaire" OR "Patient Health Questionnaire 9" OR "drug addiction" OR anxiety OR suicide OR "suicide ideation" OR "adjustment disorder" OR "adjustment disorders" OR "psychiatric disorder" OR "psychiatric disorders" OR "AIDS dementia complex" OR "mental health services" OR "substance related disorder" OR "substance related disorders" OR "community mental health services" OR "counseling" OR "medication adherence" OR "medication compliance" OR "Medication Adherence"[Mesh] OR "Counseling"[Mesh])

## Diabetes

("Diabetes Mellitus"[Mesh] OR diabetes[tiab] OR "Type 1 diabetes" OR "Type 2 diabetes" OR hyperglycaemia OR gestational diabetes OR "fasting blood sugar" OR "endocrine disorder" OR A1C OR "A1C test" OR "hemoglobin A1C" OR "glycohemoglobin test" OR HbA1c OR "Endocrine System Diseases"[Mesh] OR "Metabolic Syndrome X"[Mesh] OR "metabolic cardiovascular syndrome" OR "metabolic syndrome" OR

“metabolic syndrome X” OR “insulin resistance syndrome X” OR “metabolic X syndrome”) AND (PLWH\* OR PLWHA\* OR "people living with HIV" OR "people living with HIV/AIDS" OR "people living with" OR "people living with aids" OR "people living with hiv" OR "people living with hiv/aids" OR "people living with hiv/aids plwha" OR "people living with hiv/aids plwhas" OR "people living with hiv aids" OR "people living with hiv aids plwha" OR "people living with hiv aids plwhas" OR "people living with hiv and aids" OR "people living with hiv infection" OR "people living with hivs" OR "people living with human immunodeficiency virus" OR "people living with human immunodeficiency virus/acquired immunodeficiency syndrome" OR "people living with human immunodeficiency virus acquired immunodeficiency syndrome" OR "people livnig with hiv" OR “HIV Infections”[mesh] OR “HIV infection” OR “HIV infections” OR PLWHIV OR “HIV positive” OR “HIV-positive” OR “HIV+” OR “HIV infected” OR “HIV-infected” OR “HIV seropositivity”[mesh] OR “HIV seropositivity”) AND (LMIC OR LMICs OR "low- and middle- income countries" OR "low- and middle-income country" OR "low and middle income" OR "low- and middle- income" OR "lower middle income" OR "lmics" OR "lower middle income" OR "lower middle income countries" OR "lower middle income country" OR "lower middle income economies" OR "lower middle income setting" OR "lower middle income settings" OR Cote d’Ivoire[mesh] OR Ethiopia[mesh] OR Kenya[mesh] OR Malawi[mesh] OR South Africa[mesh] OR Uganda[mesh] OR Zambia[mesh] OR Ivory Coast[tiab] OR Cote d’Ivoire[tiab] OR Ethiopia[tiab] OR Kenya[tiab] OR Malawi[tiab] OR South Africa[tiab] OR Uganda[tiab] OR Zambia[tiab] OR "sub Saharan Africa" OR "sub-saharan Africa" OR Africa[tiab] OR Africa[mesh] OR “sub saharan Africa” OR “developing country” OR “developing countries” OR Cameroon[tiab] OR Central African Republic[tiab] OR Chad[tiab] OR Congo[tiab] OR Equatorial Guinea[tiab] OR Gabon[tiab] OR Democratic Republic of the Congo[tiab] OR Burundi[tiab] OR Djibouti[tiab] OR Ethiopia[tiab] OR Kenya[tiab] OR Rwanda[tiab] OR Somalia[tiab] OR Sudan[tiab] OR Tanzania[tiab] OR Uganda[tiab] OR Angola[tiab] OR Botswana[tiab] OR Lesotho[tiab] OR Malawi[tiab] OR Mozambique[tiab] OR Namibia[tiab] OR South Africa[tiab] OR Swaziland[tiab] OR Zambia[tiab] OR Zimbabwe[tiab] OR Benin[tiab] OR Burkina Faso[tiab] OR Cote D’ivoire OR Gambia OR Ghana OR Guinea OR Guinea-Bissau OR Liberia OR Mali OR Mauritania OR Niger[tiab] OR Nigeria[tiab] OR Senegal[tiab] OR Sierra Leone[tiab] OR Togo[tiab] OR Cameroon[mesh] OR Central African Republic[mesh] OR Chad[mesh] OR Congo[mesh] OR Equatorial Guinea[mesh] OR Gabon[mesh] OR Democratic Republic of the Congo[mesh] OR Burundi[mesh] OR Djibouti[mesh] OR Ethiopia[mesh] OR Kenya[mesh] OR Rwanda[mesh] OR Somalia[mesh] OR Sudan[mesh] OR Tanzania[mesh] OR Uganda[mesh] OR Angola[mesh] OR Botswana[mesh] OR Lesotho[mesh] OR Malawi[mesh] OR Mozambique[mesh] OR Namibia[mesh] OR South Africa[mesh] OR Swaziland[mesh] OR Zambia[mesh] OR Zimbabwe[mesh] OR Benin[mesh] OR Burkina Faso[mesh] OR Cote D’ivoire[mesh] OR Gambia[mesh] OR Ghana[mesh] OR Guinea[mesh] OR Guinea-Bissau[mesh] OR Liberia[mesh] OR Mali[mesh] OR Mauritania[mesh] OR Niger[mesh] OR Nigeria[mesh] OR Senegal[mesh] OR Sierra Leone[mesh] OR Togo[mesh] OR "Africa, Central"[Mesh] OR "Africa, Eastern"[Mesh] OR "Africa, Southern"[Mesh] OR "Africa, Western"[Mesh])

## **Cervical Cancer**

(“cervical cancer” OR uterine cervical neoplasms[mesh] OR “uterine cervical cancers” OR “uterine cervical cancer” OR “cervix neoplasms” OR “cervix neoplasm” OR “cervical neoplasms” OR “cervical neoplasm” OR “uterine cervical neoplasm” OR “uterine cervical neoplasms”) AND (PLWH\* OR PLWHA\* OR "people living with HIV" OR "people living with HIV/AIDS" OR "people living with" OR "people living with aids" OR "people living with hiv" OR "people living with hiv/aids" OR "people living with hiv/aids plwha" OR "people living with hiv/aids plwhas" OR "people living with hiv aids" OR "people living with hiv aids plwha" OR "people living with hiv aids plwhas" OR "people living with hiv and aids" OR "people living with hiv infection" OR "people living with hivs" OR "people living with human immunodeficiency virus" OR "people living with human immunodeficiency virus/acquired immunodeficiency syndrome" OR "people living with human immunodeficiency virus acquired immunodeficiency syndrome" OR "people livnig with hiv" OR “HIV Infections”[mesh] OR “HIV infection” OR “HIV infections” OR PLWHIV OR “HIV positive” OR “HIV-positive” OR “HIV+” OR “HIV infected” OR “HIV-infected” OR “HIV seropositivity”[mesh] OR “HIV seropositivity”) AND (LMIC OR LMICs OR "low- and middle- income countries" OR "low- and middle-income country" OR "low and middle income" OR "low- and middle- income" OR "lower middle income" OR "lmics" OR "lower middle income" OR "lower middle income countries" OR "lower middle income country" OR "lower middle income economies" OR "lower middle income setting" OR "lower middle income settings" OR Cote d’Ivoire[mesh] OR Ethiopia[mesh] OR Kenya[mesh] OR Malawi[mesh] OR South Africa[mesh] OR Uganda[mesh] OR Zambia[mesh] OR Ivory Coast[tiab] OR Cote d’Ivoire[tiab] OR Ethiopia[tiab] OR Kenya[tiab] OR Malawi[tiab] OR South Africa[tiab] OR Uganda[tiab] OR Zambia[tiab] OR "sub Saharan Africa" OR "sub-saharan Africa" OR Africa[tiab] OR Africa[mesh] OR “sub saharan Africa” OR “developing country” OR “developing countries” OR Cameroon[tiab] OR Central African Republic[tiab] OR Chad[tiab] OR

Congo[tiab] OR Equatorial Guinea[tiab] OR Gabon[tiab] OR Democratic Republic of the Congo[tiab] OR Burundi[tiab] OR Djibouti[tiab] OR Ethiopia[tiab] OR Kenya[tiab] OR Rwanda[tiab] OR Somalia[tiab] OR Sudan[tiab] OR Tanzania[tiab] OR Uganda[tiab] OR Angola[tiab] OR Botswana[tiab] OR Lesotho[tiab] OR Malawi[tiab] OR Mozambique[tiab] OR Namibia[tiab] OR South Africa[tiab] OR Swaziland[tiab] OR Zambia[tiab] OR Zimbabwe[tiab] OR Benin[tiab] OR Burkina Faso[tiab] OR Cote D'ivoire OR Gambia OR Ghana OR Guinea OR Guinea-Bissau OR Liberia OR Mali OR Mauritania OR Niger[tiab] OR Nigeria[tiab] OR Senegal[tiab] OR Sierra Leone[tiab] OR Togo[tiab] OR Cameroon[mesh] OR Central African Republic[mesh] OR Chad[mesh] OR Congo[mesh] OR Equatorial Guinea[mesh] OR Gabon[mesh] OR Democratic Republic of the Congo[mesh] OR Burundi[mesh] OR Djibouti[mesh] OR Ethiopia[mesh] OR Kenya[mesh] OR Rwanda[mesh] OR Somalia[mesh] OR Sudan[mesh] OR Tanzania[mesh] OR Uganda[mesh] OR Angola[mesh] OR Botswana[mesh] OR Lesotho[mesh] OR Malawi[mesh] OR Mozambique[mesh] OR Namibia[mesh] OR South Africa[mesh] OR Swaziland[mesh] OR Zambia[mesh] OR Zimbabwe[mesh] OR Benin[mesh] OR Burkina Faso[mesh] OR Cote D'ivoire[mesh] OR Gambia[mesh] OR Ghana[mesh] OR Guinea[mesh] OR Guinea-Bissau[mesh] OR Liberia[mesh] OR Mali[mesh] OR Mauritania[mesh] OR Niger[mesh] OR Nigeria[mesh] OR Senegal[mesh] OR Sierra Leone[mesh] OR Togo[mesh] OR "Africa, Central"[Mesh] OR "Africa, Eastern"[Mesh] OR "Africa, Southern"[Mesh] OR "Africa, Western"[Mesh])

**Table, Supplemental Digital Content 2.** Summary of studies that reported prevalence estimates for non-communicable diseases among HIV-infected persons in low- and middle-income countries

Author, Year	Country	Sample Size	Setting	Measurement	Prevalence	95% Confidence Interval
<i>Cardiovascular Disease</i>						
<i>Hypertension Prevalence</i>						
Amusa 2016 [1]	Nigeria	150	HIV Clinics	SBP > 140 or DBP > 90	46.0%	
Asiki 2015 [2]	Uganda	7741	WHO STEPS	SBP > 140 or DBP > 90	12.3%	
Bloomfield 2011 [3]	Kenya	12,194	HIV Clinics	SBP > 140 or DBP > 90	8.7%	
Dimala 2016 [4]	Cameroon	200	HIV Clinics	SBP > 140 or DBP > 90	28.5%	22.4-35.3%
Diouf 2012 [5]	Senegal	242	HIV Cohort	SBP > 140 or DBP > 90	28.1%	22.5-34.2%
Divala 2016 [6]	Malawi	952	HIV Clinic	SBP > 140 or DBP > 90	23.7%	21.2-26.6%
Edward 2013 [7]	Nigeria	265	HIV Clinics	SBP > 140 or DBP > 90	7.2%	
Gomes 2016 [8]	Dominican Republic	153	HIV Cohort	SBP > 140 or DBP > 90	20.0%	
Julius 2011 [9]	South Africa	304	HIV Clinic	SBP > 140 or DBP > 90	19.1%	14.7-23.5%
Kagaruki 2014 [10]	Tanzania	754	ART Clinic	SBP > 140 or DBP > 90	26.2%	
Kotwani 2013 [11]	Uganda		Community Campaign	SBP > 140 or DBP > 90	15.7%	
Kwarisiima 2016 [12]	Uganda	65000	Population Based Assessment	SBP > 140 or DBP > 90	11.0%	
Magodoro 2016 [13]	Zimbabwe	1033	Public Sector Facility	SBP > 140 or DBP > 90	10.2%	8.4-12.2%
Malaza 2012 [14]	South Africa	10,429	Population-Based Survey	SBP > 140 or DBP > 90	19.5%	



Mashinya 2014 [15]	South Africa	815	Health Center	SBP > 140 or DBP > 90	42.7%	
Mateen 2013 [16]	Uganda	5563	ART Clinic	SBP > 140 or DBP > 90	27.9%	26.7-29.1%
Menanga 2015 [17]	Cameroon	44	Hospital	SBP > 140 or DBP > 90	43.2%	
Mlay 2010 [18]	Tanzania	215	Hospital	SBP > 140 or DBP > 90	53.3%	
Muhammad 2013 [19]	Nigeria	200	Hospital	SBP > 140 or DBP > 90	9.5%	
Negin 2012 [20]	South Africa	4227	SAGE study	SBP > 140 or DBP > 90	63.0%	
Ngatchou 2013 [21]	Cameroon	204	Hospital	SBP > 140 or DBP > 90	41%	
Njelekela 2016 [22]	Tanzania	34111	ART Clinics	SBP > 140 or DBP > 90	12.5%	
Nsagha 2015 [23]	Cameroon	215	Cross-Sectional Study	SBP > 140 or DBP > 90	25.6%	15.3%-35.9%
Ogunmola 2014 [24]	Nigeria	403	Rural Tertiary Health Center	SBP > 140 or DBP > 90	14.0%	
Peck 2014 [25]	Tanzania	454	HIV Clinic	SBP > 140 or DBP > 90	16.9%	
Rabkin 2015 [26]	South Africa	175	ART Clinic	SBP > 140 or DBP > 90	37.8%	
Sander 2015 [27]	Uganda	426	ART Clinic	SBP > 140 or DBP > 90	8.0%	5.4%-10.6%
Zhou 2012 [28]	South Africa	2307	HIV Clinic	SBP > 140 or DBP > 90	20.5%	
<i>Hypertension Incidence</i>						
Okello 2015 [29]	Uganda	3389	Hospital	SBP > 140 or DBP > 90	111.5 per 1000 person-years	101.9-121.7

---

## Dyslipidemia

### *Hypercholesterolemia*



Abebe 2014 [30]	Ethiopia	462	Health Center	TC > 200	18.6%	
Asiki 2015 [2]	Uganda	7741	WHO STEPS	TC > 200	6.0%	
Daniyam 2013 [31]	Nigeria	204	HIV Clinic	TC > 200	10.4%	
Feleke 2012 [32]	Ethiopia	182	ART Clinics	TC > 200	38.2%	
Julius 2011 [9]	South Africa	304	HIV Clinic	TC > 200	32.2%	27.0-37.5%
Kagaruki 2014 [10]	Tanzania	754	ART Clinics	TC > 200	32.7%	
Kuti 2015 [33]	Nigeria	1316	ART Clinics	TC > 200	11.5%	
Muhammed 2013 [19]	Nigeria	200	HIV Clinic	TC > 200	19.0%	
Nsagha 2015 [34]	Cameroon	209	Cross-sectional Study	TC > 200	40.0%	31.8-48.2%
Ngala 2013 [35]	Ghana	305	Cross-sectional Study	TC > 200	31.9%	
Pefura 2011 [36]	Cameroon	276	Cross-sectional Study	TC > 200	30.1%	
<i>Elevated Low Density Lipoprotein (LDL)</i>						
Abebe 2014 [30]	Ethiopia	462	Health Center	LDL $\geq$ 130	17.7%	
Armstrong 2011 [37]	Tanzania	12513	HIV Clinic	LDL $\geq$ 130	12.0%	
Belay 2014 [38]	Ethiopia	141	Hospital	LDL $\geq$ 130	29.6%	
Daniyam, 2013 [31]	Nigeria	204	HIV Clinic	LDL $\geq$ 130	5.7%	
Feleke 2012 [32]	Ethiopia	182	ART Clinics	LDL $\geq$ 130	54.2%	
Julius 2011 [9]	South Africa		HIV Clinic	LDL $\geq$ 130	9.5%	6.2-12.8%
Kagaruki 2014 [10]	Tanzania	754	ART Clinics	LDL $\geq$ 130	42.9%	
Liu 2013 [39]	Tanzania	6382	HIV Clinic	LDL $\geq$ 130	12.9%	
Muhammed 2013 [19]	Nigeria	200	HIV Clinic	LDL $\geq$ 130	31.0%	

Nsagha 2015 [23]	Cameroon	215	Cross-sectional Study	LDL $\geq$ 130	29.3%	
Pefura 2011 [36]	Cameroon	276	Cross-sectional Study	LDL $\geq$ 130	33.7%	
Tadewos 2012 [40]	Ethiopia	226	HIV Clinic	LDL $\geq$ 130	33.6%	
<i>Hypertriglyceridemia</i>						
Abebe 2014 [30]	Ethiopia	462	Health Center	TG > 150	28.8%	
Armstrong 2011 [37]	Tanzania	12513	HIV Clinic	TG > 150	28.0%	
Belay 2014 [38]	Ethiopia	141	Hospital	TG > 150	32.4%	
Daniyam 2013 [31]	Nigeria	204	HIV Clinic	TG > 150	31.1%	
Feleke 2012 [32]	Ethiopia	182	ART Clinics	TG > 150	15.2%	
Julius 2011 [9]	South Africa	304	HIV Clinic	TG > 150	15.8%	11.7-19.9%
Kagaruki 2014 [10]	Tanzania	754	ART Clinics	TG > 150	16.6%	
Kuti 2015 [33]	Nigeria	1316	ART Clinics	TG > 150	27.6%	
Muhammed 2013 [19]	Nigeria	200	HIV Clinic	TG > 150	16.0%	
Nsagha 2015 [23]	Cameroon	215	Cross-sectional Study	TG > 150	19.5%	8.3-30.7%
Pefura 2011 [36]	Cameroon	276	Cross-sectional Study	TG > 150	40.9%	
Tadewos 2012 [40]	Ethiopia	226	HIV Clinic	TG > 150	55.8%	
Tesfaye 2014 [41]	Ethiopia	374	Hospital	TG > 150	45.2%	
<i>Low High Density Lipoprotein (HDL)</i>						
Abebe 2014 [30]	Ethiopia	462	Health Center	HDL-c <40	64.9%	60.0-69.3%
Asiki 2015 [2]	Uganda	7741	WHO STEPS	HDL-c <40	71.3%	
Armstrong 2011 [37]	Tanzania	12513	HIV Clinic	HDL-c <40	67.0%	

Belay 2014 [38]	Ethiopia	141	Hospital	HDL-c <40	16.9%	
Daniyam, 2013 [31]	Nigeria	204	HIV Clinic	HDL-c <40	36.8%	
Julius 2011 [9]	South Africa	304	HIV Clinic	HDL-c <40	45.7%	40.1-51.3%
Kagaruki 2014 [10]	Tanzania	754	ART Clinics	HDL-c <40	71.9%	
Liu 2013 [39]	Tanzania	6382	HIV Clinic	HDL-c <40	55.4%	
Muhammed 2013 [19]	Nigeria	200	HIV Clinic	HDL-c <40	68.5%	
Nsagha 2015 [23]	Cameroon	215	Cross-sectional Study	HDL-c <40	14.4%	
Pefura 2011 [36]	Cameroon	276	Cross-sectional Study	HDL-c <40	38.4%	
Tadewos 2012 [40]	Ethiopia	226	HIV Clinic	HDL-c <40	43.4%	
<i>Dyslipidemia*</i>						
Amusa 2016 [1]	Nigeria	150	HIV Clinic	ATP III	62.7%	
Daniyam 2013 [31]	Nigeria	204	HIV Clinic	ATP III	62.3%	
Dave 2016 [42]	South Africa	957	Health Center	ATP III	90.0%	
Kodogo 2016 [43]	Zimbabwe	103	Health Center	ATP III	67.4%	
Liu 2013 [39]	Tanzania	6382	HIV Clinic	ATP III	69.0%	
Menanga 2015 [17]	Cameroon	44	Hospital	ATP III	38.6%	
Ombeni 2016 [44]	Tanzania		HIV Clinic	ATP III	77.5%	
Omech 2012 [45]	Uganda	442	Infectious Disease Clinic	ATP III	81.5%	
Tadewos 2012 [40]	Ethiopia	226	HIV Clinic	ATP III	82.3%	

---

## **Obese and Overweight**

### *Overweight*

Asiki 2015 [2]	Uganda	7741	WHO STEPS	BMI 25-29	9.8%	
Dimala, 2016 [4]	Cameroon	200	HIV clinic	BMI 25-29	40.5%	
Divala 2016 [6]	Malawi	952	HIV clinic	BMI 25-29	13.9%	

Malaza 2012 [14]	South Africa	10,429	Population-based survey	BMI 25-29	29.3%
Muhammed 2013 [19]	Nigeria	200	Hospital	BMI 25-29	31.0%
Njelekela 2016 [22]	Tanzania	34111	ART clinics	BMI 25-29	12.7%
Nsagha 2015 [23]	Cameroon	215	cross-sectional study	BMI 25-29	32.6%
Okello 2015 [29]	Uganda	3389	HIV clinic	BMI 25-29	15.5%
Sander 2015 [27]	Uganda	426	ART clinic	BMI 25-29	10.8%
Zhou 2016 [46]	Zimbabwe	170	HIV clinic	BMI 25-29	38.8%
Zhou 2015 [47]	Zimbabwe	215	HIV clinic	BMI 25-29	19.5%

*Obesity*

Asiki 2015 [2]	Uganda	7741	WHO STEPS	BMI > 30	2.5%
Dave 2016 [42]	South Africa	957	cross-sectional study	BMI > 30	24.0%
Divala 2016 [6]	Malawi	952	HIV clinic	BMI > 30	3.8%
Malaza 2012 [14]	South Africa	10,429	Population-based survey	BMI > 30	23.8%
Muhammad 2013 [19]	Nigeria	200	Hospital	BMI > 30	6.5%
Njelekela 2016 [22]	Tanzania	34,111	ART clinics	BMI > 30	5.1%
Nsagha 2015 [23]	Cameroon	215	cross-sectional study	BMI > 30	22.3%
Ogunmola 2014 [24]	Nigeria	403	rural tertiary health center	BMI > 30	4.4%
Okello, 2015 [29]	Uganda	3389	HIV clinic	BMI > 30	3.6%
Sander 2015 [27]	Uganda	426	ART clinic	BMI > 30	4.5%
Zhou 2015 [47]	Zimbabwe	215	HIV clinic	BMI>30	18.1%

### *Overweight/Obesity*

Bloomfield 2011 [3]	Kenya	12,194	HIV clinics	BMI>25	18.0%	
Diouf 2012 [5]	Senegal	242	HIV cohort	BMI>25	28.1%	
Kagaruki 2014 [10]	Tanzania	754	ART clinics	BMI>25	26.2%	
Njelekela 2016 [22]	Tanzania	34,111	ART clinics	BMI>25	17.6%	
van Oosterhout 2012 [48]	Malawi	253	Health clinic	BMI>25	25.0%	
Zhou 2012 [28]	South Africa	2298	HIV clinic	BMI>25	57.9%	
Zhou 2015 [47]	Zimbabwe	215	HIV clinic	BMI>25	37.7%	

---

### **Diabetes**

#### *Diabetes Mellitus (DM) Definition*

Anastos 2010 [49]	Rwanda	824	Clinic	DM	2.0%	
Becker 2010 [50]	South Africa	60	Clinic	DM	3.0%	
Isa 2016 [51]	Nigeria	2632	ART Clinic	T2DM	2.3%	1.8-2.9%
Isa 2016 [51]	Nigeria	2632	ART Clinic	T2DM	5.3%	4.2-6.3%
Levitt 2016 [52]	South Africa	940	Community Health Center	WHO 1998 def	3.1%	1.4-4.8%
Levitt 2016 [52]	South Africa	940	Community Health Center	WHO 1998 def	2.3%	0.9-3.7%
Levitt 2016 [52]	South Africa	940	Community Health Center	WHO 1998 def	5.6%	1.2-9.9%
Maganga 2015 [53]	Tanzania	454	HIV Clinic	DM	18.0%	
Magodoro 2016 [13]	Zimbabwe	1033	Public Sector Facility	DM	2.1%	1.3-3.2%
Mashinya 2014 [15]	South Africa	267	Clinic	DM	13.5%	
Mohammed 2015 [54]	Ethiopia	393	Hospital	DM	6.4%	

#### *Fasting Blood Sugar (FBS)*

Amusa 2016 [1]	Nigeria	150	HIV Clinic	FBS	28.0%	
----------------	---------	-----	------------	-----	-------	--

Diouf 2012 [5]	Senegal	242	HIV Cohort	FBS > 7.0 mmol/l	14.5%	
Divala 2016 [6]	Malawi	952	HIV Clinic	FBS > 126	4.1%	3.0-5.6%
Gomes 2016 [8]	Dominican Republic	153	HIV Cohort	FBS > 126	6.0%	
Kagaruki 2014 [10]	Tanzania	754	ART Clinics	FBS > 126	4.2%	
Muhammad 2013 [19]	Nigeria	200	Hospital	FBS> or NFBS >200	3.0%	
Ngatchou 2013 [21]	Cameroon	204	Hospital	FBS > 125	2.3%	
Nsagha 2015 [34]	Cameroon	215	Cross-Sectional Study	FBS > 126	2.3%	
Tesfaye 2014 [41]	Ethiopia	374	Hospital	IDF (>100mg/dl)	33.5%	
<i>Hemoglobin A1C (HgbA1C)</i>						
Asiki 2015 [2]	Uganda	7741	WHO STEPS	HgbA1C > 6	5.6%	
Julius 2011 [9]	South Africa	304	HIV Clinic	HgbA1C > 7 or FBS > 11 mmol	1.7%	
Rhee 2016 [55]	Cameroon	500	Cross-Sectional Study	HgbA1C	3.8%	
<i>Oral Glucose Tolerance Test (OGTT)</i>						
Dave 2016 [42]	South Africa	957	Cross-Sectional Study	OGTT	3.1%	

---

## **Cervical Cancer**

### *Invasive Cervical Cancer (ICC)*

Coghill 2013 [56]	Uganda	802	Cancer Registry	ICC	48.9%	
Kafuruki 2013 [57]	Tanzania	355	Clinic-based Cross-Sectional	ICC	7.3%	
Memiah 2012 [58]	Kenya	715	ART Clinics	ICC	3.7%	

Mungo 2013 [59]	Kenya	4308	Clinic	ICC	1.3%	
Tanon 2012 [60]	Cote D'Ivoire	1017	Hospital	ICC	26.2%	
Simonds 2012 [61]	South Africa	461	Hospital	IIIB Cervical Cancer	83.1%	
<i>Cervical Intraepithelial Neoplasia (CIN)</i>						
Huchko 2014 [62]	Kenya	2338	HIV Clinic	CIN 2+	26.4%	
Jaquet 2014 [63]	Cote D'Ivoire	2998	Clinic	CIN any grade	4.4%	
Kafuruki 2013 [56]	Tanzania	355	Clinic-based Cross-Sectional	CIN	61.1%	
Kohler 2016 [64]	Malawi	824	Hospital	CIN 2+	17.3%	
Maranga 2013 [52]	Kenya	448	Hospital	CIN I	16.8%	
Memiah 2012 [57]	Kenya	715	ART Clinics	CINI, CINII, CIN III, ICC	26.7%	
Musa 2014 [65]	Nigeria	78	Hospital	CIN	11.5%	
Musa 2014 [65]	Nigeria	78	Hospital	CIN 2+	6.4%	
Njagi 2013 [66]	Kenya	350	Clinic	CIN	30.0%	
Parham 2010 [67]	Zambia	6572	Cervical Cancer	CIN2/3	33.0%	
Ramogola-Masire 2012 [68]	Botswana	2175	Community Clinic	CIN2/3	12.1%	
Wu 2016 [69]	Kenya	1054	Clinic	CIN2+	12.0%	
<i>Abnormal Cytology</i>						
Dim 2011 [70]	Nigeria	150	Hospital	SIL	12.6%	
Ezechi 2014 [71]	Nigeria	1140	Community and Clinic	SIL	79.2%	
Liu 2016 [39]	Tanzania	1365	Cross-Sectional Survey	SIL	79.2%	
Menon 2017 [72]	Kenya	599	Community	abnormal cytology	27.1%	20.9-34.0%



Mwakigonja 2012 [73]	Tanzania	170	Hospital	HSIL	41.3%	
Omar 2011 [74]	South Africa	2325	HIV Clinic	HSIL	13.5%	12.1-14.9%
Soh 2014 [75]	Kenya	441	Clinic	LSIL, HSIL	26.0%	

---

## Depression

### *Beck's Depression Inventory (BDI)*

Amiya 2014 [76]	Nepal	322	Cross-Sectional Study	BDI-Ia	25.5%	
Lawler 2011 [77]	Botswana	120	Surveillance	BDI-FS>4	38.0%	
Magidson 2016 [78]	South Africa	101	HIV Clinic	BDI-II $\geq$ 14	52.1%	
Nel 2013 [79]	South Africa	101	Convenience Sample	BDI II	40.5%	

### *Center for Epidemiologic Studies –Depression Scale (CES-D)*

Kitshoff 2012 [80]	South Africa		HIV Clinic	CES-D	62.0%	
Olisah 2015 [81]	Nigeria	310	HIV Clinic	CES-D	14.2%	
Olisah 2010 [82]	Nigeria	310	HIV Clinic	CES-D	21.3%	
Peltzer 2011 [83]	South Africa	342	Primary Health Clinic	CES-D>9	56.6%	
Peterson 2012 [84]	Gambia	252	Clinic	CES-D $\geq$ 11	7.0%	

### *Composite International Diagnostic Interview (CIDI)*

Gaynes 2012 [85]	Cameroon	400	HIV Clinic	CIDI	21.0%	
Ibrahim 2014 [86]	Nigeria	350	Hospital	CIDI	19.8%	
Nyirenda 2013 [87]	South Africa	422	Community	CIDI	42.4%	

### *Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV)*

Nakimuli-Mpungu 2011 [88]	Uganda	244	Cross-Sectional Study	DSM IV	40.0%	
Olangunju 2013 [89]	Nigeria	295	HIV Clinic	DSM IV	14.9%	

### *Hopkins Symptom Checklist (HSCL-D)*

Chan 2015 [90]	Uganda	154	HIV Clinic	HSCL-D	28.8%	
----------------	--------	-----	------------	--------	-------	--

Krumme 2015 [91]	Rwanda	610	Health Clinics	HSCL 15	47.1%
Wroe 2015 [92]	Rwanda	292	Clinic	HSCL-15 $\geq$ 1.75	11.0%
<i>Hospital Anxiety and Depression Scale (HADS)</i>					
Pappin 2012 [93]	South Africa	716	HIV Clinic	HADS $\geq$ 8	25.4%
Tesfaw 2016 [94]	Ethiopia	417	Hospital	HADS $\geq$ 8	41.2%
Yunusa 2011 [95]	Nigeria	167	Cross-Sectional Study	HADS	7.6%
<i>MINI International Neuropsychiatric Interview (MIN)</i>					
Akena 2013 [96]	Uganda	735	HIV Clinic	MINI	17.4%
Breuer 2014 [97]	South Africa	366	HIV Clinic	MINI	16.6%
Kinyanda 2016 [98]	Uganda	1099	HIV Clinic	MINI	14.1%
Mugisha 2016 [99]	Uganda	471	Population Survey	MINI	10.7%
Nakimuli-Mpungu 2013 [100]	Uganda	400	HIV Clinic	MINI	12.3%
Nakimuli-Mpungu 2011 [101]	Uganda	500	HIV Clinic	MINI	25.0%
Onyebueke 2015 [102]	Nigeria	360	HIV Clinic	MINI	27.8%
<i>Patient Health Questionnaire (PHQ9)</i>					
Ahaneku, 2016 [103]	Tanzania	205	Community	PHQ-9 $\geq$ 4	68.2%
Cerutti 2016 [104]	Lesotho	1388	Clinic	PHQ9 $\geq$ 10	28.8%
Cholera 2014 [105]	South Africa	397	Clinic	PHQ9 $\geq$ 10	36.2%
Cholera 2016 [106]	South Africa	1683	Clinic	PHQ9 $\geq$ 10	30.0%
Chibanda 2016 [107]	Zimbabwe	264	Primary health care facility	PHQ9 $\geq$ 11	68.5%
Endenshaw 2014 [108]	Ethiopia		Mixed methods Cross-Sectional Study	PHQ-9	60.0%
Kingori 2015 [109]	Kenya	312	HIV Clinic	PHQ9 $\geq$ 10	31.7%
L'Akoa R 2013 [110]	Cameroon	100	Hospital	PHQ9 $\geq$ 9	63.0%

Musisi 2014 [111]	Uganda	386	4 HIV Clinics	PHQ9 = 5-9	19.2%
Musisi 2014 [111]	Uganda	386	4 HIV Clinics	PHQ9>9	10.9%
Okeke 2013 [112]	Uganda	482	HIV Clinic	PHQ9≥9	8.3%
Onyebuchi-Iwudibia 2014 [113]	Nigeria	105	HIV Clinic	PHQ9≥10	33.3%
Pence 2014 [114]	Cameroon	55	Clinic	PHQ9	13.0%
Pence 2012 [115]	Cameroon	400	HIV Clinic	PHQ9≥10	3.0%
Shittu 2013 [116]	Nigeria	300	HIV Clinic	PHQ9≥5	56.7%
Wagner 2012 [117]	Uganda	602	HIV Clinic	PHQ9>9	13.1%
<i>Structured Clinical Interview for DSM-IV (SCID)</i>					
Chibanda 2016 [107]	Zimbabwe	264	Primary health care facility	SCID	67.0%
Obadeji 2014 [118]	Nigeria	130	Clinic	SCID	23.1%
<i>Other</i>					
Bongongo 2013 [119]	South Africa	117	HIV Clinic	Zung self-rating scale	71.8%
Chikezie 2013 [120]	Nigeria		Cross-sectional study	SCAN	29.3%
Lawler 2010 [121]	Botswana	120	Clinic	IHDS	24.0%
Marwick 2010 [122]	Tanzania	220	HIV Clinic	CIS-R	2.7%
Mwesiga 2015 [123]	Uganda	345	HIV Clinic	IASP	5.0%
Ramirez-Avila 2012 [124]	South Africa	1545	HIV Clinic	MHI-5	55.0%
Shumba 2013 [125]	Uganda	732	Clinic	Survey	59.0%
Yakob 2016 [126]	Ethiopia	485	HIV Clinics - rural and urban	Questionnaire	15.5%
Yeji 2014 [127]	South Africa	272	HIV Clinic	GHQ12	33.0%
<i>Women including pregnant women</i>					

Bailey 2016 [128]	Ukraine	180	Cross-sectional survey	Short questionnaire	27.0%
Bailey 2016 [128]	Ukraine	228	Cross-sectional survey	Short questionnaire	25.0%
Bernstein 2016 [129]	South Africa	623	Antenatal Clinic	EPDS	11.0%
Chibanda 2010 [130]	Zimbabwe	210	Clinic	DSM-IV	54.0%
Chibanda 2010 [130]	Zimbabwe	210	Clinic	EPDS $\geq$ 11	61.0%
Dow 2014 [131]	Malawi	529	Clinic	EPDS	11.5%
Hatcher 2014 [132]	Uganda	270	Prospective HIV cohort study	HSCL > 1.75	23.7%
Kaida 2014 [133]	Uganda	447	HIV Clinic	HSCL > 1.75	38.9%
Lewis 2012 [134]	Botswana	62	ID Clinic	BDI-FS	48.0%
Onono 2014 [135]	Kenya	281	9 ANCs		10.1%
Peltzer 2016 [136]	South Africa	663	Community health centers	EPDS $\geq$ 13	48.7%
Peltzer 2011 [83]	South Africa	607	PHC and community clinics	EPDS	45.1%
Sudfeld 2017 [137]	Tanzania	1487	Cohort	HSCL	57.8%
Turan 2014 [138]	Kenya	135	ANC	EPDS $\geq$ 13	25.2%
Tuthill 2016 [139]	South Africa	68	Cohort	PHQ-9>10	Antenatal 48.5%; postnatal 32.4%
Wong 2016 [140]	South Africa	625	Clinic	EPDS	11.0%
Yator 2016 [141]	Kenya	123	PMTCT Clinic	EPDS	48.0%

\*\_Dylipidemia based on the US National Cholesterol Education Program, Adult Treatment Panel III (ATP III) using conservative cutoffs: total cholesterol (TC): TC  $\geq$  200 mg/dl or 5.2 mmol/l; elevated LDL: LDL-c  $\geq$  130 mg/dl or 3.4 mmol/l; hypertriglyceridemia (TG): TG  $\geq$  150 mg/dl or 1.7 mmol/l; low HDL: HDL-c < 40 mg/dl or 1 mmol/l

SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; BMI = Body Mass Index; T2DM = Type 2 Diabetes Mellitus; NFBS = Non-Fasting Blood Sugar; IDF = International Diabetes Federation; IHDS = International HIV Dementia Scale, CIS-R = Clinical Interview Schedule Revised, IASP = International

Association of the Study of Pain, MHI-5 = Mental Health Inventory-5, EPDS = Edinburgh Postnatal Depression Scale, GHQ12 = General Health Questionnaire-12

## References

1. Amusa G, Awokola B, Isiguzo G, Onuh J, Uguru S, Oke D, et al. OS 37-02 Hypertension in HIV-infected adults in north-central Nigeria: prevalence, associated risk factors and assessment of risk using the framingham risk score. *Journal of hypertension* 2016; 34:e405.
2. Asiki G, Murphy GA, Baisley K, Nsubuga RN, Karabarinde A, Newton R, et al. Prevalence of dyslipidaemia and associated risk factors in a rural population in South-Western Uganda: a community based survey. *PloS one* 2015; 10: e0126166.
3. Bloomfield GS, Hogan JW, Keter A, Sang E, Carter EJ, Velazquez EJ, et al. Hypertension and obesity as cardiovascular risk factors among HIV seropositive patients in Western Kenya. *PloS one* 2011; 6:e22288.
4. Dimala CA, Atashili J, Mbuagbaw JC, Wilfred A, Monekosso GL. Prevalence of hypertension in HIV/AIDS patients on highly active antiretroviral therapy (HAART) compared with HAART-naive patients at the Limbe Regional Hospital, Cameroon. *PloS one* 2016; 11:e0148100.
5. Diouf A, Cournil A, Ba-Fall K, Ngom-Gueye NF, Eymard-Duvernay S, Ndiaye I, et al. Diabetes and hypertension among patients receiving antiretroviral treatment since 1998 in Senegal: prevalence and associated factors. *Isrn aids* 2012; 2012:621565.
6. Divala OH, Amberbir A, Ismail Z, Beyene T, Garone D, Pfaff C, et al. The burden of hypertension, diabetes mellitus, and cardiovascular risk factors among adult Malawians in HIV care: consequences for integrated services. *BMC public health* 2016; 16:1243.
7. Edward AO, Oladayo AA, Omolola AS, Adetiloye AA, Adedayo PA. Prevalence of traditional cardiovascular risk factors and evaluation of cardiovascular risk using three risk equations in Nigerians living with human Immunodeficiency virus. *North American Journal of Medical Sciences* 2013; 5:680-688.
8. Gomes A, Reyes EV, Garduno LS, Rojas R, Mir Mesejo G, Del Rosario E, et al. Incidence of diabetes mellitus and obesity and the overlap of comorbidities in HIV+ hispanics initiating antiretroviral therapy. *PloS one* 2016; 11:e0160797.
9. Julius H, Basu D, Ricci E, Wing J, Basu JK, Pocaterra D, et al. The burden of metabolic diseases amongst HIV positive patients on HAART attending the Johannesburg Hospital. *Current HIV research* 2011; 9:247-252.
10. Kagaruki GB, Mayige MT, Ngadaya ES, Kimaro GD, Kalinga AK, Kilale AM, et al. Magnitude and risk factors of non-communicable diseases among people living with HIV in Tanzania: a cross sectional study from Mbeya and Dar es Salaam regions. *BMC public health* 2014; 14:904.
11. Kotwani P, Kwarisiima D, Clark TD, Kabami J, Geng EH, Jain V, et al. Epidemiology and awareness of hypertension in a rural Ugandan community: a cross-sectional study. *BMC public health* 2013; 13:1151.
12. Kwarisiima D, Balzer L, Heller D, Kotwani P, Chamie G, Clark T, et al. Population-based assessment of hypertension epidemiology and risk factors among HIV-positive and general populations in rural Uganda. *PloS one* 2016; 11:e0156309.
13. Magodoro IM, Esterhuizen TM, Chivese T. A cross-sectional, facility based study of comorbid non-communicable diseases among adults living with HIV infection in Zimbabwe. *BMC research notes* 2016; 9:379.
14. Malaza A, Mossong J, Barnighausen T, Newell ML. Hypertension and obesity in adults living in a high HIV prevalence rural area in South Africa. *PloS one* 2012;7:e47761.
15. Mashinya F, Alberts M, Colebunders R, Van Geertruyden JP. Cardiovascular risk factors in a treatment-naïve, human immunodeficiency virus-infected rural population in Dikgale, South Africa. *South African Family Practice* 2014; 56:190-195.
16. Mateen FJ, Kanters S, Kalyesubula R, Mukasa B, Kawuma E, Kengne AP, et al. Hypertension prevalence and Framingham risk score stratification in a large HIV-positive cohort in Uganda. *Journal of hypertension* 2013; 31:1372-1378.
17. Menanga AP, Ngomseu CK, Jingi AM, Mfangam BM, Noubiap JJ, Gweth MN, et al. Patterns of cardiovascular disease in a group of HIV-infected adults in Yaounde, Cameroon. *Cardiovascular diagnosis and therapy* 2015; 5:420-427.
18. Mlay M, Bakari M. The prevalence of HIV among patients admitted with stroke at the Muhimbili National Hospital, Dar es Salaam, Tanzania. *Tanzania Journal of Health Research* 2010; 12.
19. Muhammad S, Sani MU, Okeahialam BN. Cardiovascular disease risk factors among HIV-infected Nigerians receiving highly active antiretroviral therapy. *Nigerian medical journal* 2013; 54:185-190.
20. Negin J, Martiniuk A, Cumming RG, Naidoo N, Phaswana-Mafuya N, Madurai L, et al. Prevalence of HIV and chronic comorbidities among older adults. *AIDS* 2012; 26( Suppl 1):S55-S63.
21. Ngatchou W, Lemogoum D, Ndobu P, Yagnigni E, Tiogou E, Nga E, et al. Increased burden and severity of metabolic syndrome and arterial stiffness in treatment-naïve HIV+ patients from Cameroon. *Vascular health and risk management* 2013; 9:509-516.
22. Njelekela M, Muhihi A, Aveika A, Spiegelman D, Hawkins C, Armstrong C, et al. Prevalence of hypertension and its associated risk factors among 34,111 HAART naive HIV-infected adults in Dar es Salaam, Tanzania. *International journal of hypertension* 2016.

23. Nsagha DS, Assob JC, Njunda AL, Tanue EA, Kibu OD, Ayima CW, et al. Risk factors of cardiovascular diseases in HIV/AIDS patients on HAART. *The open AIDS journal* 2015; 9:51-59.
24. Ogunmola OJ, Oladosu OY, Olamoyegun AM. Association of hypertension and obesity with HIV and antiretroviral therapy in a rural tertiary health center in Nigeria: a cross-sectional cohort study. *Vascular health and risk management* 2014; 10:129-137.
25. Peck RN, Shedafa R, Kalluvya S, Downs JA, Todd J, Suthanthiran M, et al. Hypertension, kidney disease, HIV and antiretroviral therapy among Tanzanian adults: a cross-sectional study. *BMC medicine* 2014; 12:125.
26. Rabkin M, Mutiti A, Chung C, Zhang Y, Wei Y, El-Sadr WM. Missed opportunities to address cardiovascular disease risk factors amongst adults attending an urban HIV clinic in South Africa. *PloS one* 2015;10:e0140298.
27. Sander LD, Newell K, Ssebowa P, Serwadda D, Quinn TC, Gray RH, et al. Hypertension, cardiovascular risk factors and antihypertensive medication utilisation among HIV-infected individuals in Rakai, Uganda. *TM & IH* 2015; 20:391-396.
28. Zhou J, Lurie MN, Barnighausen T, McGarvey ST, Newell ML, Tanser F. Determinants and spatial patterns of adult overweight and hypertension in a high HIV prevalence rural South African population. *Health & place* 2012; 18:1300-1306.
29. Okello S, Kanyesigye M, Muyindike WR, Annex BH, Hunt PW, Haneuse S, et al. Incidence and predictors of hypertension in adults with HIV-initiating antiretroviral therapy in south-western Uganda. *Journal of hypertension* 2015; 33(10): 2039-2045.
30. Abebe M, Kinde S, Belay G, Gebreegziabxier A, Challa F, Gebeyehu T, et al. Antiretroviral treatment associated hyperglycemia and dyslipidemia among HIV infected patients at Burayu Health Center, Addis Ababa, Ethiopia: a cross-sectional comparative study. *BMC research notes* 2014; 7:380.
31. Daniyam C, Iroezindu M. Lipid profile of anti-retroviral treatment-naive HIV-infected patients in Jos, Nigeria. *Annals of medical and health sciences research* 2013; 3:26-30.
32. Feleke Y, Fekade D, Mezegebu Y. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients. *Ethiopian medical journal* 2012; 50:221-230.
33. Kuti MA, Adesina OA, Awolude OA, Ogunbosi BO, Fayemiwo SA, Akinyemi JO, et al. Dyslipidemia in ART-naive HIV-infected persons in Nigeria--implications for care. *Journal of the International Association of Providers of AIDS Care* 2015; 14:355-359.
34. Nsagha DS, Weledji EP, Assob NJC, Njunda LA, Tanue EA, kibu OD, et al. Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon. *BMC cardiovascular disorders* 2015; 15.
35. Ngala RA, Fianko K. Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis. *African Health Sciences* 2013; 13:1107-1116.
36. Pefura Yone EW, Betyoumin AF, Kengne AP, Kaze Folefack FJ, Ngogang J. First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study. *AIDS research and therapy* 2011; 8:33.
37. Armstrong C, Liu E, Okuma J, Spiegelman D, Guerino C, Njelekela M, et al. Dyslipidemia in an HIV-positive antiretroviral treatment-naive population in Dar es Salaam, Tanzania. *Journal of acquired immune deficiency syndromes* 2011; 57:141-145.
38. Belay E, Seifu D, Amogne W, Kibret KT. Lipid profile derangements among human immunodeficiency virus infected adults receiving first line anti-retroviral therapy in Tikur Anbesa Specialized Hospital, Addis Ababa, Ethiopia: Comparative cross-sectional study. *Journal of AIDS and Clinical Research* 2014; 5:1-7.
39. Liu E, Armstrong C, Spiegelman D, Chalamilla G, Njelekela M, Hawkins C, et al. First-line antiretroviral therapy and changes in lipid levels over 3 years among HIV-infected adults in Tanzania. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2013; 56:1820-1828.
40. Tadewos A, Addis Z, Ambachew H, Banerjee S. Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study. *AIDS research and therapy* 2012; 9:31.
41. Tesfaye DY, Kinde S, Medhin G, Megeressa YC, Tadewos A, Tadesse E, et al. Burden of metabolic syndrome among HIV-infected patients in Southern Ethiopia. *Diabetes & metabolic syndrome* 2014; 8: 102-107.
42. Dave JA, Levitt NS, Ross IL, Lacerda M, Maartens G, Blom D. Anti-Retroviral therapy increases the prevalence of dyslipidemia in South African HIV-infected patients. *PloS one* 2016; 11:e0151911.
43. Kodogo V, Zhou DT, Oektedalen O, Duri K, Stray-Pedersen B, Gomo E. Apolipoprotein B gene polymorphisms and dyslipidemia in HIV infected adult Zimbabweans. *The open AIDS journal* 2016;10:190-198.



44. Ombeni W, Kamuhabwa AR. Lipid Profile in HIV-Infected Patients Using First-Line Antiretroviral Drugs. *Journal of the International Association of Providers of AIDS Care* 2016; 15:164-171.
45. Omech B, Sempa J, Castelnuovo B, Opio K, Otim M, Mayanja-Kizza H, et al. Prevalence of HIV-associated metabolic abnormalities among patients taking first-line antiretroviral therapy in Uganda. *Isrn aids* 2012; 960178.
46. Zhou DT, Oektedalen O, Shawarira-Bote S, Stray-Pedersen B. Changes in coronary heart disease risk profiles of HIV patients in Zimbabwe over 9 months: a follow-up study. *HIV/AIDS Research and Palliative Care* 2016;8 165-174
47. Zhou DT, Kodogo V, Chokuona KFV, Gomo E, Oektedalen O, Stray-Pedersen B. Dyslipidemia and cardiovascular disease risk profiles of patients attending an HIV treatment clinic in Harare, Zimbabwe. *HIV/AIDS Research and Palliative Care* 2015;7 145-155.
48. van Oosterhout JJ, Mallewa J, Kaunda S, Chagoma N, Njalale Y, Kampira E, et al. Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi. *PloS one* 2012; 7:e42029.
49. Anastos K, Ndamage F, Lu D, Cohen MH, Shi Q, Lazar J, et al. Lipoprotein levels and cardiovascular risk in HIV-infected and uninfected Rwandan women. *AIDS research and therapy* 2010;7.
50. Becker AC, Sliwa K, Stewart S, Libhaber E, Essop AR, Zambakides CA, et al. Acute coronary syndromes in treatment-naïve black south africans with human immunodeficiency virus infection. *Journal of Interventional Cardiology* 2010; 23:70-77.
51. Isa SE, Oche AO, Kang'ombe AR, Okopi JA, Idoko JA, Cuevas LE, et al. Human Immunodeficiency Virus and Risk of Type 2 Diabetes in a Large Adult Cohort in Jos, Nigeria. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2016; 63:830-835.
52. Levitt NS, Peer N, Steyn K, Lombard C, Maartens G, Lambert EV, et al. Increased risk of dysglycaemia in South Africans with HIV; especially those on protease inhibitors. *Diabetes research and clinical practice* 2016; 119:41-47.
53. Maganga E, Smart LR, Kalluvya S, Kataraihya JB, Saleh AM, Obeid L, et al. Glucose metabolism disorders, HIV and antiretroviral therapy among Tanzanian adults. *PloS one* 2015; 10:e0134410.
54. Mohammed AE, Shenkute TY, Gebisa WC. Diabetes mellitus and risk factors in human immunodeficiency virus-infected individuals at Jimma University Specialized Hospital, Southwest Ethiopia. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy* 2015; 8:197-206.
55. Rhee JY, Bahtila TD, Palmer D, Tih PM, Aberg JA, LeRoith D, et al. Prediabetes and diabetes among HIV-infected adults in Cameroon. *Diabetes Metab Res Rev* 2016; 32:544-549.
56. Coghill AE, Newcomb PA, Madeleine MM, Richardson BA, Mutyaba I, Okuku F, et al. Contribution of HIV infection to mortality among cancer patients in Uganda. *AIDS* 2013; 27:2933-2942.
57. Kafuruki L, Rambau PF, Massinde A, Masalu N. Prevalence and predictors of Cervical Intraepithelial Neoplasia among HIV infected women at Bugando Medical Centre, Mwanza-Tanzania. *Infectious agents and cancer* 2013; 8:45.
58. Memiah P, Mbuthia W, Kiiru G, Agbor S, Odhiambo F, Ojoo S, et al. Prevalence and risk factors associated with precancerous cervical cancer lesions among HIV-infected women in resource-limited settings. *AIDS research and treatment* 2012; 953743.
59. Mungo C, Cohen CR, Maloba M, Bukusi EA, Huchko MJ. Prevalence, characteristics, and outcomes of HIV-positive women diagnosed with invasive cancer of the cervix in Kenya. *International journal of gynaecology and obstetrics* 2013; 123:231-235.
60. Tanon A, Jaquet A, Ekouevi DK, Akakpo J, Adoubi I, Diomande I, et al. The spectrum of cancers in West Africa: associations with human immunodeficiency virus. *PloS one* 2012; 7:e48108.
61. Simonds HM, Wright JD, du Toit N, Neugut AI, Jacobson JS. Completion of and early response to chemoradiation among human immunodeficiency virus (HIV)-positive and HIV-negative patients with locally advanced cervical carcinoma in South Africa. *Cancer* 2012; 118:2971-2979.
62. Huchko MJ, Leslie H, Maloba M, Bukusi EA, Cohen CR. Factors associated with recurrence of cervical intraepithelial neoplasia 2+ after treatment among HIV-infected women in Western Kenya. *Journal of acquired immune deficiency syndromes* 2014; 66:188-192.
63. Jaquet A, Horo A, Ekouevi DK, Toure B, Coffie PA, Effi B, et al. Risk factors for Cervical Intraepithelial Neoplasia in HIV-infected women on antiretroviral treatment in Côte d'Ivoire, West Africa. *PloS one* 2014; 9.
64. Kohler RE, Tang J, Gopal S, Chinula L, Hosseinipour MC, Liomba NG, et al. High rates of cervical cancer among HIV-infected women at a referral hospital in Malawi. *International journal of STD & AIDS* 2016; 27:753-760.
65. Musa J, Achenbach C, Taiwo B, Berzins B, Silas O, Daru PH, et al. High-risk human papilloma virus and cervical abnormalities in HIV-infected women with normal cervical cytology. *Infectious agents and cancer* 2014:36.

66. Njagi SK, Mugo NR, Reid AJ, Satyanarayana S, Tayler-Smith K, Kizito W, et al. Prevalence and incidence of cervical intra-epithelial neoplasia among female sex workers in Korogocho, Kenya. *Public health action* 2013; 3:271-275.
67. Parham GP, Mwanahamuntu MH, Sahasrabudde VV, Westfall AO, King KE, Chibwesa C, et al. Implementation of cervical cancer prevention services for HIV-infected women in Zambia: measuring program effectiveness. *HIV therapy* 2010; 4:703-722.
68. Ramogola-Masire D, de Klerk R, Monare B, Ratshaa B, Friedman HM, Zetola NM. Cervical cancer prevention in HIV-infected women using the "see and treat" approach in Botswana. *Journal of acquired immune deficiency syndromes* 2012; 59:308-313.
69. Wu TJ, Smith-McCune K, Reuschenbach M, von Knebel Doeberitz M, Maloba M, Huchko MJ. Performance of p16INK4a ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study. *BMJ open* 2016; 6:e012547.
70. Dim CC, Ezegwui HU, Ikeme AC, Nwagha UI, Onyedum CC. Prevalence of cervical squamous intraepithelial lesions among HIV-positive women in Enugu, South-eastern Nigeria. *Journal of obstetrics and gynaecology* 2011; 31:759-762.
71. Ezechi OC, Ostergren PO, Nwaokorie FO, Ujah IA, Odberg Pettersson K. The burden, distribution and risk factors for cervical oncogenic human papilloma virus infection in HIV positive Nigerian women. *Virology journal* 2014; 11:5.
72. Menon S, van den Broeck D, Rossi R, Ogbe E, Mabeya H. Multiple HPV infections in female sex workers in Western Kenya: implications for prophylactic vaccines within this sub population. *Infectious agents and cancer* 2017; 12:2.
73. Mwakigonja AR, Torres LM, Mwakyoma HA, Kaaya EE. Cervical cytological changes in HIV-infected patients attending care and treatment clinic at Muhimbili National Hospital, Dar es Salaam, Tanzania. *Infectious agents and cancer* 2012; 7:3.
74. Omar T, Schwartz S, Hanrahan C, Modisenyane T, Tshabangu N, Golub JE, et al. Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort. *AIDS* 2011; 25:87-94.
75. Soh J, Rositch AF, Koutsky L, Guthrie BL, Choi RY, Bosire RK, et al. Individual and partner risk factors associated with abnormal cervical cytology among women in HIV-discordant relationships. *International journal of STD & AIDS* 2014; 25:315-324.
76. Amiya RM, Poudel KC, Poudel-Tandukar K, Pandey BD, Jimba M. Perceived family support, depression, and suicidal ideation among people living with HIV/AIDS: a cross-sectional study in the Kathmandu Valley, Nepal. *PloS one* 2014; 9:e90959.
77. Lawler K, Jeremiah K, Mosepele M, Ratcliffe SJ, Cherry C, Seloilwe E, et al. Neurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana. *PloS one* 2011; 6:e17233.
78. Magidson JF, Saal W, Nel A, Remmert JE, Kagee A. Relationship between depressive symptoms, alcohol use, and antiretroviral therapy adherence among HIV-infected, clinic-attending patients in South Africa. *Journal of health psychology* 2016.
79. Nel A, Kagee A. The relationship between depression, anxiety and medication adherence among patients receiving antiretroviral treatment in South Africa. *AIDS care* 2013; 25(8): 948-955.
80. Kitshoff C, Campbell L, Naidoo SS. The association between depression and adherence to antiretroviral therapy in HIV-positive patients, KwaZulu-Natal, South Africa. *South African Family Practice* 2012; 54:145-150.
81. Olisah VO, Adekeye O, Sheikh TL. Depression and CD4 cell count among patients with HIV in a Nigerian University Teaching Hospital. *International journal of psychiatry in medicine* 2015; 48:253-261.
82. Olisah VO, Baiyewu O, Sheikh TL. Adherence to highly active antiretroviral therapy in depressed patients with HIV/AIDS attending a Nigerian university teaching hospital clinic. *Afr J Psychiatry* . 2010;13(4):275-9.
83. Peltzer K, Shikwane ME. Prevalence of postnatal depression and associated factors among HIV-positive women in primary care in Nkangala District, South Africa. *Southern African Journal of HIV Medicine*. 2011(42):24-8.
84. Peterson K, Togun T, Klis S, Menten J, Colebunders R. Depression and posttraumatic stress disorder among HIV-infected Gambians on antiretroviral therapy. *AIDS patient care and STDs* 2012; 26:589-596.
85. Gaynes BN, Pence BW, Atashili J, O'Donnell J, Kats D, Ndumbe PM. Prevalence and predictors of major depression in HIV-infected patients on antiretroviral therapy in Bamenda, a semi-urban center in Cameroon. *PloS one* 2012; 7:e41699.
86. Ibrahim AW, Jidda MS, Wakil MA, Rabbebe IB, Omeiza AB, Yusuph H, et al. Prevalence, correlates and under-diagnosis of clinical depression among adults on highly active antiretroviral therapy in a tertiary health institution in northeastern Nigeria. *Journal of Public Health in Africa* 2014; 5:93-98.

87. Nyirenda M, Chatterji S, Rochat T, Mutevedzi P, Newell ML. Prevalence and correlates of depression among HIV-infected and -affected older people in rural South Africa. *Journal of affective disorders* 2013; 151:31-38.
88. Nakimuli-Mpungu E, Munyaneza, G. Depression, alcohol abuse, and the disclosure of HIV serostatus among rural HIV-positive individuals in western Uganda. *Neurobehavioral HIV Medicine* 2011;19-25.
89. Olagunju AT, Ogundipe OA, Erinfolami AR, Akinbode AA, Adeyemi JD. Toward the integration of comprehensive mental health services in HIV care: an assessment of psychiatric morbidity among HIV-positive individuals in sub-Saharan Africa. *AIDS care* 2013; 25:1193-1198.
90. Chan BT, Weiser SD, Boum Y, Haberer JE, Kembabazi A, Hunt PW, et al. Declining prevalence of probable depression among patients presenting for antiretroviral therapy in rural Uganda: the role of early treatment initiation. *AIDS and behavior* 2015; 19:19-26.
91. Krumme AA, Kaigamba F, Binagwaho A, Murray MB, Rich ML, Franke MF. Depression, adherence and attrition from care in HIV-infected adults receiving antiretroviral therapy. *Journal of epidemiology and community health* 2015; 69:284-289.
92. Wroe EB, Hedt-Gauthier BL, Franke MF, Nsanzimana S, Turinimana JB, Drobac P. Depression and patterns of self-reported adherence to antiretroviral therapy in Rwanda. *International journal of STD & AIDS* 2014; 26:257-261.
93. Pappin M, Wouters E, Booyesen FL. Anxiety and depression amongst patients enrolled in a public sector antiretroviral treatment programme in South Africa: a cross-sectional study. *BMC public health* 2012; 12:244.
94. Tesfaw G, Ayano G, Awoke T, Assefa D, Birhanu Z, Miheretie G, et al. Prevalence and correlates of depression and anxiety among patients with HIV on-follow up at Alert Hospital, Addis Ababa, Ethiopia. *BMC psychiatry* 2016; 16:368.
95. Yunusa MA, Obembe A, Ibrahim T, Njoku CH. Prevalence and specific psychosocial factors associated with substance use and psychiatric morbidity among patients with HIV infection at Usmanu Danfodiyo University Teaching Hospital, Sokoto state, Nigeria. *African Journal of Drug and Alcohol Studies* 2011; 10:11-16.
96. Akena D, Joska J, Obuku EA, Stein DJ. Sensitivity and specificity of clinician administered screening instruments in detecting depression among HIV-positive individuals in Uganda. *AIDS care* 2013; 25:1245-1252.
97. Breuer E, Stoloff K, Myer L, Seedat S, Stein DJ, Joska JA. The validity of the Substance Abuse and Mental Illness Symptom Screener (SAMISS) in people living with HIV/AIDS in primary HIV care in Cape Town, South Africa. *AIDS and behavior* 2014; 18:1133-1141.
98. Kinyanda E, Weiss HA, Levin J, Nakasujja N, Birabwa H, Nakku J, et al. Incidence and Persistence of Major Depressive Disorder Among People Living with HIV in Uganda. *AIDS and behavior* 2016.
99. Mugisha JO, Schatz EJ, Randell M, Kuteesa M, Kowal P, Negin J, et al. Chronic disease, risk factors and disability in adults aged 50 and above living with and without HIV: findings from the wellbeing of older people study in Uganda. *Global health action* 2016; 9:31098.
100. Nakimuli-Mpungu E, Mojtabei R, Alexandre PK, Musisi S, Katabira E, Nachega JB, et al. Lifetime depressive disorders and adherence to anti-retroviral therapy in HIV-infected Ugandan adults: a case-control study. *Journal of affective disorders* 2013; 145:221-226.
101. Nakimuli-Mpungu E, Musisi S, Katabira E, Nachega J, Bass J. Prevalence and factors associated with depressive disorders in an HIV+ rural patient population in southern Uganda. *Journal of affective disorders* 2011; 135:160-167.
102. Onyebueke GC, Okwaraji FE. Depression and suicide risk among HIV positive individuals attending an out patient HIV/Aids clinic of a Nigerian Tertiary Health institution. *African Journal of Psychiatry (South Africa)* 2015; 18.
103. Ahaneku H, Ross MW, Nyoni JE, Selwyn B, Troisi C, Mbwambo J, et al. Depression and HIV risk among men who have sex with men in Tanzania. *AIDS care* 2016; 28(Suppl 1):140-147.
104. Cerutti B, Broers B, Masetibi M, Faturiyeye O, Toti-Mokoteli L, Motlatsi M, et al. Alcohol use and depression: link with adherence and viral suppression in adult patients on antiretroviral therapy in rural Lesotho, Southern Africa: a cross-sectional study. *BMC public health* 2016; 16:947.
105. Cholera R, Gaynes BN, Pence BW, Bassett J, Qangule N, Macphail C, et al. Validity of the Patient Health Questionnaire-9 to screen for depression in a high-HIV burden primary healthcare clinic in Johannesburg, South Africa. *Journal of affective disorders* 2014; 167:160-166.
106. Cholera R, Pence BW, Gaynes BN, Bassett J, Qangule N, Pettifor A, et al. Depression and engagement in care among newly diagnosed HIV-infected adults in Johannesburg, South Africa. *AIDS and behavior* 2016.
107. Chibanda D, Verhey R, Gibson LJ, Munetsi E, Machando D, Rusakaniko S, et al. Validation of screening tools for depression and anxiety disorders in a primary care population with high HIV prevalence in Zimbabwe. *Journal of affective disorders* 2016; 198:50-55.

108. Endeshaw M, Walson J, Rawlins S, Dessie A, Alemu S, Andrews N, et al. Stigma in Ethiopia: association with depressive symptoms in people with HIV. *AIDS care* 2014; 26:935-939.
109. Kingori C, Haile ZT, Ngatia P. Depression symptoms, social support and overall health among HIV-positive individuals in Kenya. *International journal of STD & AIDS* 2015; 26:165-172.
110. L'Akoa R M, Noubiap JJ, Fang Y, Ntone FE, Kuaban C. Prevalence and correlates of depressive symptoms in HIV-positive patients: a cross-sectional study among newly diagnosed patients in Yaounde, Cameroon. *BMC psychiatry* 2013; 13:228.
111. Musisi S, Wagner GJ, Ghosh-Dastidar B, Nakasujja N, Dickens A, Okello E. Depression and sexual risk behaviour among clients about to start HIV antiretroviral therapy in Uganda. *International journal of STD & AIDS* 2014; 25:130-137.
112. Okeke EN, Wagner GJ. AIDS treatment and mental health: evidence from Uganda. *Social science & medicine* 2013; 92:27-34.
113. Onyebuchi-Iwudibia O, Brown A. HIV and depression in Eastern Nigeria: the role of HIV-related stigma. *AIDS care* 2014; 26:653-657.
114. Pence BW, Gaynes BN, Atashili J, O'Donnell JK, Kats D, Whetten K, et al. Feasibility, safety, acceptability, and preliminary efficacy of measurement-based care depression treatment for HIV patients in Bamenda, Cameroon. *AIDS and behavior* 2014; 18:1142-1151.
115. Pence BW, Gaynes BN, Atashili J, O'Donnell JK, Tayong G, Kats D, et al. Validity of an interviewer-administered patient health questionnaire-9 to screen for depression in HIV-infected patients in Cameroon. *Journal of affective disorders* 2012; 143:208-213.
116. Shittu RO, Issa BA, Olanrewaju GT, Mahmoud AO, Odeigah LO, Salami AK, et al. Prevalence and correlates of depressive disorders among people living with HIV/AIDS, in north central Nigeria. *Journal of AIDS and Clinical Research* 2013; 4.
117. Wagner GJ, Ghosh-Dastidar B, Garnett J, Kityo C, Mugenyi P. Impact of HIV antiretroviral therapy on depression and mental health among clients with HIV in Uganda. *Psychosomatic medicine* 2012; 74:883-890.
118. Obadeji A, A OO, T OA. Prevalence and predictors of depression in people living with HIV/AIDS attending an outpatient clinic in Nigeria. *Iranian journal of psychiatry and behavioral sciences* 2014; 8:26-31.
119. Bongongo T, Tumbo J, Govender I. Depressive features among adult patients receiving antiretroviral therapy for HIV in Rustenburg district, SA. *South African Journal of Psychiatry* 2013; 19:31-34.
120. Chikezie UE, Otakpor AN, Kuteyi OB, James BO. Depression among people living with human immunodeficiency virus infection/acquired immunodeficiency syndrome in Benin City, Nigeria: a comparative study. *Nigerian journal of clinical practice* 2013; 16:238-242.
121. Lawler K, Mosepele M, Ratcliffe S, Seloilwe E, Steele K, Nthobatsang R, et al. Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study. *Journal of the International AIDS Society* 2010; 13:15.
122. Marwick KF, Kaaya SF. Prevalence of depression and anxiety disorders in HIV-positive outpatients in rural Tanzania. *AIDS care* 2010; 22:415-419.
123. Mwesiga EK, Mugenyi L, Nakasujja N, Moore S, Kaddumukasa M, Sajatovic M. Depression with pain co morbidity effect on quality of life among HIV positive patients in Uganda: a cross sectional study. *Health and quality of life outcomes* 2015; 13:206.
124. Ramirez-Avila L, Regan S, Giddy J, Chetty S, Ross D, Katz JN, et al. Depressive Symptoms and Their Impact on Health-seeking Behaviors in Newly-diagnosed HIV-infected Patients in Durban, South Africa. *AIDS and behavior* 2012; 16:2226-2235.
125. Shumba CS, Atuhaire L, Memiah P, Atukunda R. Assessment of community mobilization and home-based HIV counselling and testing offered by health facilities in rural Uganda. *African journal of reproductive health* 2013; 17:171-176.
126. Yakob B, Purity Ncama B. Client satisfaction: correlates and implications for improving HIV/AIDS treatment and care services in southern Ethiopia. *International health* 2016; 8:292-298.
127. Yeji F, Klipstein-Grobusch K, Newell M-L, Hirschhorn LR, Hosegood V, Bärnighausen T. Are social support and HIV coping strategies associated with lower depression in adults on antiretroviral treatment? Evidence from rural KwaZulu-Natal, South Africa. *AIDS care* 2014; 26:1482-1489.
128. Bailey H, Malyuta R, Semenenko I, Townsend CL, Cortina-Borja M, Thorne C. Prevalence of depressive symptoms in pregnant and postnatal HIV-positive women in Ukraine: a cross-sectional survey. *Reproductive health* 2016; 13:27.
129. Bernstein M, Phillips T, Zerbe A, McIntyre JA, Brittain K, Petro G, et al. Intimate partner violence experienced by HIV-infected pregnant women in South Africa: a cross-sectional study. *BMJ open* 2016; 6:e011999.

130. Chibanda D, Mangezi W, Tshimanga M, Woelk G, Rusakaniko P, Stranix-Chibanda L, et al. Validation of the Edinburgh Postnatal Depression scale among women in a high HIV prevalence area in urban Zimbabwe. *Archives of women's mental health* 2010; 13:201-206.
131. Dow A, Dube Q, Pence BW, Van Rie A. Postpartum depression and HIV infection among women in Malawi. *Journal of acquired immune deficiency syndromes* 2014; 65:359-365.
132. Hatcher AM, Woollett N, Pallitto CC, Mokoatle K, Stöckl H, MacPhail C, et al. Bidirectional links between HIV and intimate partner violence in pregnancy: implications for prevention of mother-to-child transmission. *Journal of the International AIDS Society* 2014; 17:19233.
133. Kaida A, Matthews LT, Ashaba S, Tsai AC, KanTERS S, Robak M, et al. Depression during pregnancy and the postpartum among HIV-infected women on antiretroviral therapy in Uganda. *Journal of acquired immune deficiency syndromes* 2014; 67(Suppl 4):S179-S187.
134. Lewis EL, Mosepele M, Seloilwe E, Lawler K. Depression in HIV-positive women in Gaborone, Botswana. *Health care for women international* 2012; 33:375-386.
135. Onono MA, Cohen CR, Jerop M, Bukusi EA, Turan JM. HIV serostatus and disclosure: implications for infant feeding practice in rural south Nyanza, Kenya. *BMC public health* 2014; 14:390.
136. Peltzer K, Rodriguez VJ, Jones D. Prevalence of prenatal depression and associated factors among HIV-positive women in primary care in Mpumalanga province, South Africa. *SAHARA J : journal of Social Aspects of HIV/AIDS* 2016; 13:60-67.
137. Sudfeld CR, Kaaya S, Gunaratna NS, Mugusi F, Fawzi WW, Aboud S, et al. Depression at antiretroviral therapy initiation and clinical outcomes among a cohort of Tanzanian women living with HIV. *AIDS* 2017; 31:263-271.
138. Turan B, Stringer KL, Onono M, Bukusi EA, Weiser SD, Cohen CR, et al. Linkage to HIV care, postpartum depression, and HIV-related stigma in newly diagnosed pregnant women living with HIV in Kenya: a longitudinal observational study. *BMC Pregnancy and Childbirth* 2014; 14:400.
139. Tuthill EL, Pellowski JA, Young SL, Butler LM. Perinatal depression among HIV-infected women in KwaZulu-Natal South Africa: prenatal depression predicts lower rates of exclusive breastfeeding. *AIDS and behavior* 2017; 21:1691-1698.
140. Wong M, Myer L, Zerbe A, Phillips T, Petro G, Mellins CA, et al. Depression, alcohol use, and stigma in younger versus older HIV-infected pregnant women initiating antiretroviral therapy in Cape Town, South Africa. *Archives of women's mental health* 2017; 20:149-159.
141. Yator O, Mathai M, Vander Stoep A, Rao D, Kumar M. Risk factors for postpartum depression in women living with HIV attending prevention of mother-to-child transmission clinic at Kenyatta National Hospital, Nairobi. *AIDS care* 2016; 28:884-889.